Literature DB >> 23652938

Long-term follow-up of neurological manifestations in a boy with incontinentia pigmenti.

Lucia Margari1, Anna Linda Lamanna, Maura Buttiglione, Francesco Craig, Maria G Petruzzelli, Vanessa Terenzio.   

Abstract

Incontinentia pigmenti (IP) is an X-linked dominant genodermatosis confined to females. It is usually lethal in males. However, the survival of some males has been reported in literature. We describe a long follow-up case of a 12-year-old male with IP and a normal karyotype but a genomic deletion of the NEMO gene in the Xq28 position in the form of somatic mosaicism. The patient showed severe ophthalmic abnormalities and neurological manifestations characterised by very mild cerebellar ataxia and a history of epilepsy that was severe at the beginning with West syndrome, become moderate overtime and is now resolved. Despite these neurological manifestations, probably related to the presence of at least some mutated cells in his brain, the long-term follow-up in this patient demonstrated good neurological and cognitive outcome.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23652938     DOI: 10.1007/s00431-013-2021-8

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  10 in total

1.  [On the genetics of incontinentia pigmenti].

Authors:  W LENZ
Journal:  Ann Paediatr       Date:  1961

Review 2.  Genodermatoses caused by genetic mosaicism.

Authors:  M Vreeburg; M A M van Steensel
Journal:  Eur J Pediatr       Date:  2012-11-01       Impact factor: 3.183

3.  Incontinentia pigmenti case series: clinical spectrum of incontinentia pigmenti in 53 female patients and their relatives.

Authors:  T A Phan; O Wargon; A M Turner
Journal:  Clin Exp Dermatol       Date:  2005-09       Impact factor: 3.470

Review 4.  Incontinentia pigmenti (Bloch-Sulzberger syndrome).

Authors:  S J Landy; D Donnai
Journal:  J Med Genet       Date:  1993-01       Impact factor: 6.318

5.  Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia.

Authors:  A Jain; C A Ma; S Liu; M Brown; J Cohen; W Strober
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

Review 6.  Incontinentia pigmenti, a chromosomal instability syndrome, is associated with childhood malignancy.

Authors:  W M Roberts; J J Jenkins; E L Moorhead; E C Douglass
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

7.  Incontinentia pigmenti in a newborn male infant with DNA confirmation.

Authors:  J L Roberts; B Morrow; C Vega-Rich; C M Salafia; H M Nitowsky
Journal:  Am J Med Genet       Date:  1998-01-13

Review 8.  Incontinentia pigmenti in a male infant with Klinefelter syndrome: a case report and review of the literature.

Authors:  Evelina Buinauskaite; Jurate Buinauskiene; Vesta Kucinskiene; Dale Strazdiene; Skaidra Valiukeviciene
Journal:  Pediatr Dermatol       Date:  2010-08-27       Impact factor: 1.588

Review 9.  Neurological findings in incontinentia pigmenti; a review.

Authors:  Marije E C Meuwissen; Grazia M S Mancini
Journal:  Eur J Med Genet       Date:  2012-05-04       Impact factor: 2.708

10.  Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium.

Authors:  A Smahi; G Courtois; P Vabres; S Yamaoka; S Heuertz; A Munnich; A Israël; N S Heiss; S M Klauck; P Kioschis; S Wiemann; A Poustka; T Esposito; T Bardaro; F Gianfrancesco; A Ciccodicola; M D'Urso; H Woffendin; T Jakins; D Donnai; H Stewart; S J Kenwrick; S Aradhya; T Yamagata; M Levy; R A Lewis; D L Nelson
Journal:  Nature       Date:  2000-05-25       Impact factor: 49.962

  10 in total
  1 in total

Review 1.  Human Genetic Diseases Linked to the Absence of NEMO: An Obligatory Somatic Mosaic Disorder in Male.

Authors:  Alessandra Pescatore; Ezia Spinosa; Carmela Casale; Maria Brigida Lioi; Matilde Valeria Ursini; Francesca Fusco
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.